top of page

Technology

LifeMatrix develops a unique bio-engineering technology to grow human replacement tissues in the laboratory as next generation implants for the treatment of cardiovascular diseases.

>

About us

LifeMatrix Technologies AG, is a pre-revenue, high-tech startup company spun out of the Institute for Regenerative Medicine at the University of Zurich.

>

Team

Our team combines world leading science in cardiovascular tissue engineering with in-depth entrepreneurial expertise in medical biomimetic device development. 

>

Press & News

Innosuisse Start-up Innovation Project

2023

LifeMatrix has been awarded with a Start-up Innovation Project from Innosuisse, the Swiss Innovation Agency.

Read More

Medical Tech Outlook

2023

LifeMatrix Technologies has been awarded as the top cardiovascular medtech startup of 2023 by Med Tech Outlook.

Read More

Pionierpreis

2022

The Pionierpreis is considered one of the most important innovation prizes in Switzerland and a significant award for young companies.

Read More

EACTS

2021

Our CEO, Maximilian Emmert gives an interview in the EACTS News about his experience winning the Techno Collage Innovation Award.

Read More

VentureKick

2021

LifeMatrix wins CHF 150,000 to develop groundbreaking biomimetic implants designed to grow and regenerate with patients.

Read More

VentureKick

2021

LifeMatrix under Global Game Changers in the annual report by Venture Kick.

Read More

VentureLeaders

2020

LifeMatrix has been chosen by a jury of investors into the Swiss National Startup Team for Venture Leaders Life Sciences 2020 from over 60 applicants.

Read More

VentureKick

2020

LifeMatrix wins VentureKicks financial support.

Read More

Medical Device Network

2019

GlobalData: LifeMatrix set to disrupt cardiovascular implant market.

Read More

Diagnostic and Interventional Cardiology

2019

Tissue Engineering Will Disrupt Cardiovascular Implant Market.

Read More

Biba Medtech Insights

2019

Interview with Maximilian Emmert about the problems of transcatheter aortic valve implantation and how LifeMatrix could be the solution. 

Read More

University of Zurich

2019

Three Million Euros Awarded to Two UZH Researchers.

Read More

GlobalData

2018

Study uses simulations to predict cultured heart valve growth. 

Read More

Science Daily

2018

Computer-designed customized regenerative heart valves.

Read More

Science Daily

2018

Computer-designed customized regenerative heart valves.

Read More

Blick

2018

Kindern sollen Herzklappen aus dem Labor helfen.

Read More

Handelszeitung

2017

Künstliche Herzklappe wächst mit dem Kind.

Read More

Biomimetic Solutions for Life

Award winning technology

Active in the field of biomimetic implants, LifeMatrix develops human cell derived, off-the-shelf available tissue engineered implants, which transform into living tissue after implantation and have the capacity to grow and regenerate with the patient.

 

The award winning technology is the result of multiple national and international research grants and is backed by more than 20 years of research with over 100 peer-reviewed publications.

 

Extensive preclinical (animal) studies demonstrated safety and efficacy and allow the technology to be translated in to clinical application.

Awards & Support

bottom of page